Anthracycline-induced cardiorenal toxicity: from molecular mechanisms to clinical management
Frontiers in Cardiovascular Medicine · 12.05.2026 · 13
DOI: 10.3389/fcvm.2026.1811848 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 12.05.2026. Verfasst von Linke Jiao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Major Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
In oncology clinics, anthracyclines remain a cornerstone of cancer therapy. However, their clinical benefits are accompanied by substantial toxicities. As cumulative exposure increases and patient survival improves, the incidence of treatment-related adverse effects also increases, particularly those affecting the heart and kidneys. Rather than existing in isolation, these two forms of damage often interact: impaired cardiac function can accelerate renal injury through hemodynamic changes and neuroendocrine activation, whereas renal dysfunction further exacerbates cardiac injury via toxin accumulation and inflammation. This interaction leads to the well-recognized cardiorenal vicious cycle, which substantially limits the safe use of anthracyclines in clinical practice. Although dexrazoxane is currently the only approved cardioprotective agent, its renoprotective effect remains limited. Moreover, there are no clear guidelines or standardized strategies for preventing or managing anthracycline-induced cardiorenal toxicity. Therefore, a deeper understanding of the underlying mechanisms, along with effective monitoring and intervention strategies, is crucial for optimizing anthracycline therapy and improving patient survival. This review explores the pathological basis, molecular mechanisms, risk factors, monitoring approaches, and treatment strategies related to anthracycline-induced cardiorenal toxicity. It aims to develop a comprehensive strategy to protect both cardiac and renal function and to provide a scientific foundation for the development of safer and more effective cancer treatment regimens.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
- Department of Breast Surgery, Dezhou Second People's Hospital, Dezhou, China.
- Department of Breast Surgery, Xingtai People's Hospital, Xingtai, China.
- Department of Breast Surgery, North China University of Science and Technology Affiliated Hospital, Tangshan, China.
- Department of Critical Care Medicine, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
- Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Förderung
- National Science and Technology Major Project
- National Natural Science Foundation of China
Zitieren
APA
Jiao, L., Yuan, C., Wang, L., Zhao, Y., Zhang, G., Yang, X., Gao, Y., Yang, F., Li, X., An, N., Shang, H., & Xing, Y. (2026). Anthracycline-induced cardiorenal toxicity: from molecular mechanisms to clinical management. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1811848
Vancouver
Jiao L, Yuan C, Wang L, Zhao Y, Zhang G, Yang X, et al. Anthracycline-induced cardiorenal toxicity: from molecular mechanisms to clinical management. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1811848
BibTeX
@article{Jiao2026,
author = {Jiao, Linke and Yuan, Chao and Wang, Li and Zhao, Yating and Zhang, Guoxia and Yang, Xinyu and Gao, Yonghong and Yang, Fan and Li, Xinye and An, Na and Shang, Hongcai and Xing, Yanwei},
title = {Anthracycline-induced cardiorenal toxicity: from molecular mechanisms to clinical management},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1811848}
}
EUVIMED